PHARMACOLOGICAL ADVANCES IN PAIN MANAGEMENT CURRENT TRENDS AND FUTURE PROSPECT

Swarna Lichika Satman*[1], Archana Rathore[2],

Pushkar Vishwakarma [3], Haripriya Pandey [4], Vishal Dewangan [5]

Chandrashekhar Manjhi[6], Aastha Jha[7]

Address- [1,2] Associate Professor at Danteswari College of Pharmacy,494221

[3] Under graduate Student at Kalinga University Raipur ,492101

[4,5,6,7] Under graduate Student at Danteswari College of Pharmacy,494221

ABSTRACT:

Traditional approaches to pain management have given way to more sophisticated, multifaceted strategies. The development of pain treatments is examined in this review, starting with conventional opioid-based approaches and their drawbacks. Safer substitutes have been made possible by notable developments in non-opioid pharmacological options, such as COX-2 inhibitors and cannabinoids. Ion channels, nerve growth factor inhibitors, and inflammatory mediators are examples of emerging targets that hold promise for novel treatments of neuropathic and chronic pain. Thanks to genetic profiling and personalized medicine, customized treatments are now more effective and have fewer side effects. Furthermore, non-pharmacological adjuncts in conjunction with multimodal approaches emphasize the value of comprehensive care for special populations and the necessity of sophisticated pain management techniques. The ethical and legal issues surrounding the adoption of new treatments are also covered in this review. In the future, developments in pharmacogenomics.

KEY WORD: Nociceptive pain, neuropathic pain, Cytochrome p-450, cyclooxygenase(COX), Analgesia, NSAIDs, opioids .

INTRODUCTION:

Pain serves as a defensive technique of the human body in response to stimulants, often indicating the presence of disease. The irritation of free nerve endings in pain receptors, is what causes this pain. Various chemical mediators, including histamine, leukotrienes, substance P, acetylcholine, bradykinin, and prostaglandins, are implicated in this process. Furthermore, these mediators contribute to vasodilation, vasoconstriction, and changes in capillary permeability at the injury location[1]. describing it as a distressing sensory and emotional experience that is either related to or resembles feelings connected to real or possible tissue damage[2]. The experience of ache is common among individuals at different stages of life, and it often serves as a symptom of multiple diseases. This complexity makes it challenging to determine the exact prevalence of pain[3]. This release activates nearby neurons, generating a

chain of electrical signals that move toward the spinal Colum. Additionally, these signals are propagated along neural pathways, including the spinothalamic tract. Once in the spinal Colum, secondary neurons relay the signals to higher brain regions[4]. its benign lower back pain is particularly troubling, as it mainly impacts people in mid-life, resulting in disability during their most economically productive years[5].

The concept of pain is often learned through experiences of injury during childhood. Researchers have determined that stimuli that elicit pain are typically associated with potential tissue harm. Nonetheless, a significant number of individuals express discomfort without any identifiable physiological cause, often due to psychological factors. Misconceptions about the connection between pain and tissue damage can arise for both patients and healthcare professionals. It is vital to acquire and validate a person's claim of ache, regardless of the ability to identify a damaging stimulus[6]. The generality of nerve pain is largely indeterminate, primarily due to a lack of epidemiological research. Additionally, it is estimated that between

25% and 50% of all pain clinic visits are associated with this condition. It is estimated that central neuropathic pain affects between 2% and 8% of individuals who have suffered a stroke[3]. Understanding pain's neurobiology is essential because of the significant burden it places on both patients and society. In recent years, there have been limited major breakthroughs that have led to effective treatments or interventions for critical pain. Most of the available options have been in use for many years and tend to offer only marginal long-term benefits. Furthermore, the challenges posed by side effects, drug interactions (such as those involving analgesics and co-analgesics), and the potential for drug misuse significantly hinder effective pain management[7]. The majority of analgesics on the market today still rely on older medications or drug classes that were first developed for other ailments, such



Fig. 1- Pathophysiology of Neuropathic Pain

anticonvulsants and antidepressants, despite a wealth of information on pain processes and significant investments in research and development[8]. The lack of effective preoperative pain management consultations and educational initiatives has instilled a fear of inadequate postoperative pain relief, causing patients to seek more opioids than necessary[9]. A variety of

new pharmacological treatments are being explored, targeting molecular pathways involved in neuropathic pain. It is crucial that these new medications not only provide effective pain relief but also offer a more favourable side effect profile compared to current drugs in the same class[10].

Nerve pain can arise from a wide variety of neurological untidiness that effect the nervous system. Additionally, chronic ache may manifest in neurological conditions where the underlying cause remains unidentified[11]. The remembrance of nerve pain as a national public health issue highlights its severe physical and societal implications[12]. The human body has a built-in mechanism for regulating pain, yet the details of these mechanisms are not completely understood. allowing only a limited number of pain signals to be transmitted at any given time, which may result in their interference with one another. The body also features an endogenous opioid system that releases enkephalins, endorphins, and dynorphins to facilitate pain regulation.

Additionally, a descending inhibitory nervous system, influenced by norepinephrine and serotonin, regulates the types of nociceptive information that can be relayed from the periphery

to the brain[13]. A crucial aspect of effectively treating pain is the precise evaluation of postsurgical ache[14]. Given the established treatment strategies for neuropathic cancer pain (NCP), accurate diagnosis is essential. It can be difficult to diagnose NCP and calls for a comprehensive assessment that involves a full medical history, physical examination, and possibly diagnostic testing[15]. A thorough comprehension of the postoperative ache experience from the patient's potential is imperative for healthcare professionals to discover methods for improving care. This study sought to characterize the postoperative pain experience, assess how satisfied patients are with their painkillers, assess the success of educational efforts directed at patients, and investigate patient perceptions regarding postoperative pain and the medications prescribed for its alleviation[16]. A lack of engagement in physical activity may now be leading to adverse physical and mental consequences for the patient. The persistent ache is a source of distress, and the discrepancy between the pain experienced and the actual tissue damage can be confusing for the patient[6]. Psychological factors, including emotional and behavioural responses. Strategies for analgesics, that do not take these interactions into account are likely to result in frustration and failure[17]. A primary challenge faced during this process was the quest for a logical principle of classification that is acceptable for the diverse types of chronic ache. The definitions of pain categories vary significantly, often depending on the position of the ache (e.g., headaches), its etiology (e.g., pain associated with cancer), or the anatomical system that is primarily impacted (e.g., neuropathic pain)[18]. The goal was to detail their involvement and pleasure with the management of this pain[16]. These pains are frequently identified as 'neuropathic' or'psychogenic,' distinguishing them from 'nociceptive' pain, which is associated with physical origins like trauma or inflammation[19]. offer a preliminary assessment of how well this

national approach is working to improve practices[20]. Neck Pain is a vital factor in the incidence of disability worldwide. The estimates demonstrate that the prevalence and burden of Neck ache are markedly elevated on a global scale[21]. Around 1.5 billion people globally are affected by chronic pain. The debilitating nature of this pain can transform every aspect of an individual's daily life, frequently resulting in persistent emotional and psychological challenges[22].

TRADITIONAL APPROACHES TO PAIN MANAGEMENT:

Recently, there has been a notable increase in the awareness of the limitations and risks tied to conventional pain management practices, especially concerning the possible for addiction and the side effects of long-term opioid use. This awareness has led to a growing interest in alternative and complementary therapies that offer additional pathways for pain relief. Acupuncture, herbal medicine, and mindfulness techniques are examples of such therapies that have garnered attention for their potential benefits in managing pain[23]. The advancement of our knowledge regarding the exploration of the implement and element link with the complex nature of ache has led to a deeper understanding of patient care for individuals experiencing pain. This has resulted in improvements across various domains, including surgical procedures, interventional methods, medication management, physiotherapy, and complementary approaches[24]. For many years, researchers and clinicians have relied on a biomedical perspective to explore, diagnose, and treat pain, which has centred on the sensory and neurological processes and the symptoms associated with pain. Unfortunately, this model has fallen short in addressing the specific variables that pertain to each patient[25]. Anaesthetic is a important aspect of healthcare, aiming to reduce the ache and discomfort caused by various medical conditions. Improving patients' functional abilities, general well-being, and quality of life all depend on effective pain management[23]. People with chronic pain and the general public need to understand each other better. To combat stigma and misconceptions about chronic ache[24]. The commonness of narcotics abuses and compulsion has increased in the context of painkiller use that is prescribed [26]. Many individuals have found that pharmaceutical therapy for chronic pain is safe and effective; however, for best results, clinical expertise and regular reconsideration are needed. Certain medications may not be appropriate, especially for elderly patients and those with compromised hepatic or renal systems.



Fig. 2- Chronic pain treatment and digital patient engagement methods

Several earlier recommendations were for adults, not children or the elderly who are experiencing neuropathic pain. Pharmacokinetic drug-drug interactions are possible in all patients who take several medications. Individuals who were with greater education, worse health, and an integrated approach to health, as well as those seeking symptom relief or an improvement in their overall state, are more likely to use herbal therapies [27,28].

ADVANCES IN NON-OPIOID PAIN MANAGEMENT:

Kehlet and his associates first proposed the idea of "balanced" or multimodal analgesia in the early 1990s. This approach aimed to enhance surgical outcomes by combining opioid and nonopioid analgesics, thereby reducing the side effects typically associated with opioids[29]. The national opioid outbreak crisis has been compounded by the overprescription of opioids and lack of consideration for alternative nonopioid treatments. Over $700 billion is thought to be spent each year on opioid use[30]. Since the starting dose for strong opioids is regulated and determined by safety considerations rather than pain severity, all oncologists should be skilled in starting these medications[31]. Changes in motivation, mood, and attention accompany all forms of pain, which intensifies the sensory disruption. It is still unclear how closely the sensitive and affective aspects of ache are related mechanistically[32]. In conjunction with other postoperative multimodal analgesic techniques, pre-incisional rather than surgical nerve blockage is likely to provide the best results for managing postoperative pain[33]. Neuroendocrine, immune, and ectodermal cells, along with central and peripheral neurons, all express three distinct types of narcotic receptors: mu, delta, and kappa[34]. Opioids have been used for pain relief since 3000 BCE, when opium was first utilized[35]. The pursuit for better methods of managing pain is still in progress. This could include ideas for combating antibiotic resistance as well as innovative approaches to drug development, like nonprofit pharmaceutical companies and public-private partnerships[34]In opioid research, the following plan are currently being follow:

- **Abuse-deterrent formulations:** One strategy to address the addiction issue in opioid research involves creating "abuse-deterrent" formulations. This can be achieved by making the opioids more resistant to crushing, chewing, or by incorporating adversary that produce unpleasant effects if misused.

- **Augmenting endogenous opioid mechanisms:** Neutral endopeptidase and aminopeptidase N can quickly break down endogenous opioid peptides. Several animal models and early human trials have demonstrated that blocking this breakdown by constraint, has analgesic effects.
- **Multivalent ligands:** Opioid receptors, along with other G protein-coupled receptors, have the ability to form dimers or oligomers. Research is currently focused on multivalent

- **ligands that contain** different pharmacophores targeting various receptors. The basic idea is that minimizing negative effects may be achieved by combining agonist and antagonist qualities at various opioid or nonopioid receptors.

The sensation of pain begins with activation of primary afferents within the autonomic nervous system; noxious stimuli are communicated by nociceptors to the dorsal root ganglion. Although all parts of the nerve's express voltage-gated sodium channels, only specific classes of these channels are involved in peripheral nerve nociception transmission [36]. Clinical decision-making is difficult for clinicians because they have a lot of options when prescribing pharmacotherapy. While there is evidence that opioids and NSAIDs may improve pain and physical function similarly, opioids have a significantly higher rate of adverse events[37].



Fig: 3-Role of selective COX Inhibitors

NSAIDs can be divided as either non-selective, which block both constitutive and inducible, or selective, which target only COX-2. These inhibitors act through varying degrees of competitive inhibition, which can be either reversible or irreversible. NSAIDs provide antipyretic, analgesic, and anti-platelet effects, making them useful in both acute and chronic conditions, and they also help reduce symptoms of various allergic reactions[38].

EMERGING PHARMACOLOGICAL TARGETS:

In addition to being a global health concern, pain is a natural part of being human. Acute pain can occasionally act as a warning sign to keep someone safe, but it can also develop into a pathological condition that needs major medical care[39]. Based on the etiology, targeted approaches are being promoted for the treatment of pain syndromes. source are now being asked to categorize ache based on its symptomatology, such as nociceptive, neuropathic, inflammatory, somatic, or visceral, in addition to considering its underlying pathology[40]. Endogenous opioids, such as endorphins and enkephalins, block pain transmission by binding to these opioid receptors[41]. Some patients may not be able to use non-opioid analgesics due to their potential side effects. NSAIDs may result in gastrointestinal (GI) side effects, including peptic ulcer disease, nausea, vomiting, and dyspepsia[4].

- **Nerve Growth Factor:**
  In research that began over fifty years ago, neuropathic factor was identified as a substance that stimulated the growth of neurons in developing chick embryos. After the protein was

purified, it was only much later that it was discovered to be a member of a structurally related protein family[42]. The neurotrophins family of secreted proteins includes nerve growth factor, which has multiple functions in the development and operation of the adult nervous system[43]. These factors have notable structural similarities and a common ancestor gene[44]. Despite being a well-known neuropeptide, NGF as well mediates inflammation, pain, and itching[45,46].

- **Ion channel Modulator:**

The complex combination of positive and negative sensory phenomena that characterize neuropathic syndromes frequently includes paroxysmal or persistent paraesthesia and hypersensitivity[47]. Therefore, Sodium channels are crucial for numerous physiological processes, including neurotransmission, secretion, skeletal and cardiac muscle contraction, and nerve conduction([48]. In classical electrochemistry, the voltage clamp method was used to clarify the fundamental functional characteristics of sodium and calcium channels. NaV channels quickly become active and start the action potential when nerve or muscle fibres depolarize. Fast inactivation of sodium channels occurs in a matter of milliseconds, bringing the sodium conductance through them almost back to its initial level[49].

- **Cannabinoids:**

Cannabis sativa has been utilized for medicinal purposes, including pain relief, for thousands of years. Studies have looked into the effects of administering cannabinoids intracerebrally, particularly in animal models of swelling. Different types of pain are directly antinociceptive affected by cannabinoids. Cannabinoid ligands' well-established CB1R-mediated analgesic effects are constrained by their adverse effect profile[50]. Cannabis is commonly known as marijuana. The two distinct G protein-coupled receptors (GPCRs) activated by cannabinoids are classified as metabotropic receptors.This kinase phosphorylates a channel protein, resulting in changes to ionic permeability[51].

- **Sigma receptors:**

Sigma receptors were believed to be an opioid receptor type in 1976. σ1 and σ2, two kinds of ligand-biased protein chaperones, are now recognized by our growing knowledge of sigma receptors[52]. Sigma-1 receptors are predominantly discover in the membranes of the ER, particularly in areas where the ER is closely associated with mitochondria at the subcellular level[53].

- **Orexin receptor antagonists:**

A small number of neurons located in the lateral and dorsal parts of the hypothalamus produce the two isoforms, orexin-A and orexin-B[54]. Orexin-A has a comparable affinity for both receptors, while orexin-B has a higher affinity for OX2R compared to OX1R. This orexin system is remarkably conserved among various species[56].

NEUROPATHIC PAIN MANAGEMENT:

One way to define pain is as an unpleasant emotional and sensory experience linked to, or akin to, the sensations produced by actual or potential damage to bodily tissues. Those afflicted with neuropathic ache often report experiencing either continuous or sporadic spontaneous pain. Although a variety of descriptors may be relevant, neuropathic pain is often conveyed through terms such as burning, shooting, pricking, tingling, squeezing, or freezing[57]. Estimates suggest that about 5% of the population suffers from neuropathic ache. However, the

mechanistic approach to alleviating the pain experienced by these patients often falls short, and many do not achieve adequate analgesia through their current pain management therapies[58]. The development of neuropathic pain is often linked to lesions within the somatic sensory system, which can be induced by physical injury. Additionally, damage to the central somesthesis, frequently due to stroke, trauma, or neurodegeneration, can also lead to this pain.



Fig. 4 – Pain management overview

The relative ease of conducting experiments on the peripheral nervous system has facilitated a deeper understanding of neuropathic ache mechanisms, particularly through investigations into hypersensitivity following targeted lesions of peripheral nerves[59].

Chronic neuropathy arises from a complex and multifaceted etiology. elevated amounts of inflammatory mediators' sensitive afferent neurons and can cause pain on its own without the need for painful external stimuli[60]. Identifying and comprehension the underlying mechanisms of pain perception is imperative for selecting the most appropriate treatment. Nociceptive pain occurs when pain receptors are stimulated, usually due to injuries and swelling. Common examples include ischemia, arthritis, infections, trauma, and tissue deformation[61]. The stimulation of pain receptors is the primary cause of pain, if it is reported. Common analgesic drugs are used to treat this type of ache, which is known as nociceptive pain. Many new pharmacological treatments targeting molecules involved in neuropathic pain are currently under investigation. In addition to providing efficient pain relief, new medications should also have a better side effect profile than those in the same class[10].

Numerous neurologic pain patients do not receive the proper care for their pain, according to epidemiological surveys. This could be the result of poor diagnostic precision, a lack of knowledge about the pathophysiological mechanisms underlying pain, comparatively ineffective medications, and a lack of awareness regarding the effective medications and how to use them appropriately in clinical settings. Patients with neuropathic pain are increasingly being offered alternative. In standard clinical practice, most patients receive a combination of these therapeutic approaches for more comprehensive management[28].

PERSONALISED MEDICINE IN PAIN MANAGEMENT:

Personalized medicine is defined as the customization of therapeutic interventions for defined patient groups, determined by their likelihood of responding to treatment or their risk of experiencing adverse effects. This contemporary concept has arisen from significant advancements in the understanding of genomics and molecular medicine[62]. Medications, particularly opioids and nonopioids, play a crucial role in analgesia. Nonetheless, the wide-ranging interindividual variability in both therapeutic effects and adverse reactions can lead to a protracted process in determining the right medication and dosage for each patient, occasionally resulting in hazards for some individuals. Pharmacogenomics is the discipline that explores the genetic differences responsible for individual variations in drug responses[63] The education of healthcare professionals in pain medicine is necessary for improving the comprehension, evaluation, and treatment of pain. It is crucial for these professionals to acquire specialized expertise to meet the varied requirements of patients suffering from pain. Additionally, advocacy within this medical domain is vital for increasing awareness, fostering policy reforms, and tackling inequalities in pain management[64].

Pharmacogenomics examines how genetic variations among individuals influence pharmacokinetics and pharmacodynamics. These genetic differences become evident in clinical practice, where patients show a wide range of responses to medications[65].This study is essential for the advancement and execution of viable services that deliver tangible clinical, and humanistic benifits to both patients and healthcare systems[66]. The significance of pharmacogenomics is on the rise as an effective method for promoting objective, safe, and personalized medication prescribing. It is essential to clarify the distinction between the two terms; "pharmacogenomics" involves the study of how variations in multiple genes, including both DNA and RNA, affect drug responses, while "pharmacogenetics" is restricted to variations in DNA[67].

It is the study of how different people react to medication therapy and the processes behind varying drug response using information derived from transcriptomics, proteomics, metabolomics, and genomics. The effectiveness and toxicity of many medications are influenced by genetic differences between individuals in the transporters and enzymes that metabolize medicines[68].To make therapy modifications in situations where pharmacogenetic factors affect interindividual variability in medication response, access to the patient's genotype will be required. Numerous hospitals in Scandinavia provide blood sample-based cytochrome P450 enzyme genotyping, in which medication metabolic capability is determined by inherited mutations in encoding genes [69].

Acute pain functions as an essential indicator of potentially harmful stimuli or dangerous scenarios. It effectively prevents interaction with these stimuli and situations, while simultaneously providing protection to damaged tissues as they recover[70]. In a recent publication by the National Academy of Medicine, which examines the current and prospective role of artificial intelligence (AI) in healthcare, the authors identified "unprecedented opportunities" for enhancing specialist care. They pointed out that AI can assist in managing the challenges of human limitations, such as fatigue and inattention, as well as the dangers posed by machine errors. The digitization of health data and the rapid integration of technology are propelling significant changes and progress in the utilization of AI in healthcare[71]. Patients with inadequate treatment outcomes frequently exhibit various immune biomarker

abnormalities, which has led to an increased focus on the targeting of immune system mechanisms as a means of implementing precision medicine in psychiatric practice[72].

NON- PHARMACOLOGICAL ADJUNCTS AND MULTIMODAL THERAPY:

Nociceptor detection is the responsibility of the back bone, which also transmits and modulates pain signals. These three main parts make up the pain pathway. Specialized sensory receptors called nociceptors transform painful inputs into electrical signals in response[73]. Although adjunctive therapy is time-based and can be used as a component of multimodal therapy, it is not the same as multifaceted therapy. Instead, it is the endeavour to enhance the effectiveness of one treatment with another. Thus, to increase the effectiveness of a single treatment, many supplementary therapies can be administered[74]. The efficacy of multimodal treatment for ADHD in kids and teenagers is not well supported by the available data. Two independent investigations comparing highly structured group cognitive behavioural therapy (CBT) with non-specific therapeutic care in people with ADHD produced contradictory findings. However, systematic studies have not shown any proof, thus more research is required to fully understand this problem[75].

Acute ache can be effectively managed with opioids. Despite being used for decades to treat chronic pain, mostly because there aren't enough studies on the subject[76]. Multimodal analgesia maximizes pain relief by targeting multiple sites along the nociceptive pathway—the route through which pain from tissue injury is perceived—using complementary mechanisms of action. Pharmacological and nonpharmacological approaches are both included in multimodal analgesia[77].

This approach could establish a new paradigm for managing acute postoperative pain, which may also enable doctors to better manage the pain of patients who don't fit the sample[77]. It is commonly known that goal-setting is essential for organizing pharmacological therapies, and we have previously emphasized how important this is. With passive goals, the focus of treatment is on the productive symptoms of upper motor neuron syndrome, and single interventions may have greater effects without requiring as much or as frequent exercise or occupational therapy. An approach to therapy that emphasizes "more is better" has been put out in regard to active goals in order to help patients comprehend that the more exercise they do and the more often they do it, the more likely they are to reach their objective [74].

PAIN MANAGEMENT IN SPECIAL POPULATION:

Anxiety before surgery is common in both patients and caregivers. Reduced anxiety is linked to patient education, and nonpharmacologic techniques enhance calmness and optimistic thinking as part of a multimodal strategy for managing pain. Music therapy and guided imagery are examples of perioperative cognitive behavioural therapies that are non-invasive and unlikely to cause harm, even though there is not enough evidence to strongly recommend any particular approach. Analgesia and narcotic avoidance may benefit from their beneficial effects on lowering anxiety, but more research is required[78]. There are physiological, sensory, affective, behavioural, cognitive, and sociocultural aspects to the pain experience. Assessing the symptoms of ache in adults is simpler[79]. Reduced gastric acid secretion, slowed

gastrointestinal motility, decreased total absorption surface area, decreased splanchnic blood flow, smaller liver size, decreased liver blood flow, decreased glomerular filtration, and decreased renal tubular function are all signs of aging-related changes in the gastrointestinal tract, liver, and kidneys[80].

The creation of novel strategies to lessen pain and anxiety in paediatric patients is essential since these conditions can cause people to avoid seeking medical attention[81]. Even lower is the proportion of patients who exhibit symptoms that could indicate neuropathic pain. In the majority of preclinical animal models of neuropathic pain, nearly every animal displays behaviours that point to allodynia and hyperalgesia[82]. Access to pain management is restricted by socioeconomic and other environmental issues, which also exacerbate or complicate pain. The likelihood of poorly managed pain is increased by factors such as poverty, physical labour, lack of access to support and employment, isolation from friends, family, or medical professionals, and substandard housing. One major underlying issue is frequently a lack of financial resources. Disparities in the availability and acceptance of pain management are frequently linked to poverty and social marginalization[83].

Finding and creating safe, effective, non-addictive painkillers is fraught with difficulties. To date, for instance, the majority of clinical trials have failed due to ineffectiveness[84]. In addition to having a wide range of pathophysiologic mechanisms and meanings, pain can vary greatly in intensity, quality, and duration. As a result, it can be difficult to define pain in a clear and accurate way[85]. The issue of accessing optimal pain management is compounded by significant disparities in healthcare access, which are widely recognized in both the traditional biomedical system and in services that adopt a more holistic biopsychosocial model. Usually, attempts to identify and address care imbalance centre on the lack of funding for healthcare and the scarcity of scarce resources[83].

REGULATORY AND ETHICAL CONSIDERATIONS:

Assessing chronic pain can also have an impact on a person's level of protection under disability law. chronic pain is a major problem in a variety of legal situations[86]. When it is appropriate, medical personnel—especially doctors—should give all the details regarding their patients' conditions. It is their duty to give patients and, if required, their decision-makers thorough knowledge on cutting-edge medical techniques that can be applied to end-of-life care[87].

The most common cause of years spent disabled worldwide, particularly in developing nations, is chronic painful conditions. One Nearly 40 million adults in the US are estimated to have moderate to severe chronic ache, and roughly 10 million of them are more disabled than those with other crippling chronic conditions like stroke or renal failure[88]. Compared to the general population, cancer survivors have a tenfold lower opioid-related mortality rate. However, the number of opioid-related deaths among cancer patients is rising, which is believed to be connected to longer-term opioid therapy, higher levels of chronic pain, and improved survival. Concerns regarding undertreated cancer pain have been raised by numerous clinicians in response to increased regulation of opioid prescriptions[89]. Nurses must make decisions based on information that is both objective and subjective, patient and provider perceptions, and the advantages and disadvantages of treating opioids. Clinical nurses may encounter conflict when

attempting to balance a patient's request for pain management with their physiological state, possible treatment outcomes, and personnel bias[90].

The majority of nations' legislative frameworks are the outcome of extensive consultations with committees made up of academics, research organizations, veterinarians, legal and ethical experts, and representatives of animal welfare organizations. Regardless of whether the research will find an audience, all animal-based studies are now more closely examined before they start to make sure they are necessary, properly justified, and have the right material and environmental context and design for their behaviour[91]. Drug regulatory agencies (DRAs) have adopted the emerging field of regulatory science (RS) to improve the scientific basis for their benefit/risk assessments and regulatory decisions, ensuring they are grounded in the best available science. The Drug Administration views RS as a science that develops new methods, standards, and instruments to evaluate the performance, quality, safety, and efficacy of all goods under FDA regulation[92]. The conventional "one-size-fits-all" approach to medicine is beginning to give way to more individualized approaches thanks to recent developments in biological therapy[93].

FUTURE PROSPECTS IN PAIN MANAGEMENT:

With millions of people globally affected by chronic pain, which significantly impacts both the economy and society, pain management remains a critical healthcare issue. Opioids, NSAIDs, and anticonvulsants are among the pharmacological treatments currently available, but they are typically inefficient for managing chronic pain or have a number of undesirable side effects, such as tolerance, reliance, gastrointestinal harm, and cardiovascular hazards. Alternative medicines that can effectively relieve pain without the hazards associated with opioids are desperately needed, as the opioid crisis has highlighted. Small molecule inhibitors that target particular pain-related proteins and G-protein-coupled receptor (GPCR) modulators are two of the most promising avenues. Key targets for non-opioid pain management have been identified as GPCRs, which are essential for cellular signalling and pain regulation. In order to prevent addiction, these modulators can relieve pain by acting on pain pathways without activating the reward system [94]. Individuals with chronic, incapacitating pain who do not respond to current treatments may have an option thanks to these precision-targeted therapies, which are expected to significantly improve pain management [95].

Neuromodulation technologies are becoming useful tools in the treatment of chronic ache at the exact time as these pharmaceutical developments. Neuromodulation is the process of altering the nerves' activity, either inside the brain or at the spinal cord level, by applying electrical or magnetic stimulation. Spinal cord stimulation (SCS), one of the most important advancements in neuromodulation, has been demonstrated to be successful in treating pain in diseases like complex regional pain syndrome (CRPS). Conventional SCS devices interfere with the brain's ability to perceive pain by sending constant electrical pulses to the spinal cord. But thanks to developments in SCS technology, closed-loop spinal cord stimulators have been created, which modify the stimulation parameters in response to the patient's nervous system's real-time feedback [96].

The future of pain care is moving toward more individualized and precision-based methods as our understanding of pain grows. Since pain is subjective by nature, each person's perception and reaction to pain are greatly influenced by their unique genetic, neurological, and

environmental characteristics. Genetic testing might assist in identifying patients who could be more susceptible to negative side effects from specific medications, like NSAIDs or opioids, enabling more individualized and knowledgeable treatment decisions [97]. In addition to genetics, neuroimaging techniques such as functional MRI and positron emission tomography are providing unprecedented insights into the brain's pain processing mechanisms. These techniques enable researchers and clinicians to observe how pain signals are transmitted and processed in real-time, which could help identify biomarkers of pain and improve the diagnosis and treatment of pain disorders [98]. Furthermore, regenerative medicine, which includes treatments based on stem cells, has great potential to address the root causes of chronic ache. For individuals with nerve injuries or degenerative diseases that result in persistent pain, stem cells may be able to replace or repair damaged tissue in the nervous systems, providing a long-term cure [99].

CONCLUSION:

In conclusion, common medications used to manage ache include opioids, nonsteroidal anti-inflammatory drugs, anticonvulsants, and antidepressants. Acute ache can be effectively managed with opioids, but long-term use carries risks such as tolerance, dependence, and addiction. Even while NSAIDs can help with inflammatory ache, the possibility of side effects such renal failure and gastrointestinal bleeding restricts their use. Neuropathic pain is increasingly being treated with anticonvulsants and antidepressants, which have shown promise in lowering pain levels and enhancing function. To balance the advantages and disadvantages of treatment, careful patient selection and dosage are required because many medications might also have adverse effects[100]. Anaesthesiologists, surgeons, nurses, physical therapists, administrators, and other medical professionals involved in patient care must work closely together to develop the best postoperative recovery services. While improving perioperative care is a continuous process that is aided by clinical research, major advancements in clinical practice should be made immediately with a wider use of methods that are known to improve recovery and rehabilitation rather than waiting for more research data[101].

REFERENCES:

1. Babaie S, Taghvimi A, Hong JH, Hamishehkar H, An S, Kim KH. Recent advances in pain management based on nanoparticle technologies. Vol. 20, Journal of Nanobiotechnology. BioMed Central Ltd; 2022.
2. Vinkel MN, Rackauskaite G, Finnerup NB. Classification of pain in children with cerebral palsy. Vol. 64, Developmental Medicine and Child Neurology. John Wiley and Sons Inc; 2022. p. 447–52.
3. Karabin O'neil C. LEARNING OBJECTIVES Pain Management.
4. Alorfi NM. Pharmacological Methods of Pain Management: Narrative Review of Medication Used. Int J Gen Med. 2023 Jul;Volume 16:3247–56.
5. Smith JA, Osborn M. Pain as an assault on the self: An interpretative phenomenological analysis of the psychological impact of chronic benign low back pain. Psychol Health. 2007 Jul;22(5):517–34.
6. Steeds CE. The anatomy and physiology of pain. Vol. 27, Surgery. 2009. p. 507–11.

7. Mouraux A, Bannister K, Becker S, Finn DP, Pickering G, Pogatzki-Zahn E, et al. Challenges and opportunities in translational pain research – An opinion paper of the working group on translational pain research of the European pain federation (EFIC). European Journal of Pain (United Kingdom). 2021 Apr 1;25(4):731–56.

8. Giraud F, Pereira E, Anizon F, Moreau P. Recent advances in pain management: Relevant protein kinases and their inhibitors. Vol. 26, Molecules. MDPI AG; 2021.

9. Chen Q, Chen E, Qian X. A narrative review on perioperative pain management strategies in enhanced recovery pathways—the past, present and future. Vol. 10, Journal of Clinical Medicine. MDPI; 2021.

10. van Velzen M, Dahan A, Niesters M. Neuropathic Pain: Challenges and Opportunities. Vol. 1, Frontiers in Pain Research. Frontiers Media S.A.; 2020.

11. Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A, Treede RD. Challenges of neuropathic pain: focus on diabetic neuropathy. Vol. 127, Journal of Neural Transmission. Springer; 2020. p. 589–624.

12. Vanila LM, Alan S, Kaye D, Hirsch JA, Manchikanti L, Kaye ÁAD, et al. Lessons for Better Pain Management in the Future: Learning from the Past. Available from: https://doi.org/10.6084/m9.figshare.12155850.

13. Paladini A, Barrientos Penaloza J, Plancarte Sanchez R, Ergönenç T, Varrassi G. Bridging Old and New in Pain Medicine: An Historical Review. Cureus. 2023 Aug 17;

14. Gao L, Mu H, Lin Y, Wen Q, Gao P. Review of the Current Situation of Postoperative Pain and Causes of Inadequate Pain Management in Africa. Vol. 16, Journal of Pain Research. Dove Medical Press Ltd; 2023. p. 1767–78.

15. Mestdagh F, Steyaert A, Lavand'homme P. Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques. Vol. 30, Current Oncology. Multidisciplinary Digital Publishing Institute (MDPI); 2023. p. 6838–58.

16. Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Vol. 30, Current Medical Research and Opinion. 2014. p. 149–60.

17. Hudspith MJ, Siddall PJ, Munglani R. Physiology of Pain.

18. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Vol. 156, Pain. Lippincott Williams and Wilkins; 2015. p. 1003–7.

19. Bromm B, Lorenz J. Neurophysiological evaluation of pain. 1998.

20. Alford DP, Zisblatt L, Ng P, Hayes SM, Peloquin S, Hardesty I, et al. SCOPE of pain: An evaluation of an opioid risk evaluation and mitigation strategy continuing education program. Pain Medicine (United States). 2016 Jan 1;17(1):52–63.

21. Vassilaki M, Hurwitz Dc EL. Insights in Public Health Perspectives on Pain in the Low Back and Neck: Global Burden, Epidemiology, and Management. Vol. 73. 2014.

22. Chakravarthy K V., Boehm FJ, Christo PJ. Nanotechnology: A promising new paradigm for the control of pain. Vol. 19, Pain Medicine (United States). Oxford University Press; 2018. p. 232–43.

23. Farooq S. Integrative Approaches to Pain Management: Combining Conventional and Alternative Therapies. Vol. 1, Frontiers in Healthcare Technology. 2024.

24. Mackey S. Future Directions for Pain Management. Lessons from the Institute of Medicine Pain Report and the National Pain Strategy. Vol. 32, Hand Clinics. W.B. Saunders; 2016. p. 91–8.

25. Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. Vol. 131, Postgraduate Medicine. Taylor and Francis Inc.; 2019. p. 185–98.

26. Elkbuli A, Stotsenburg M, Epstein C, Calvert K, Boneva D, McKenney M, et al. A Multidisciplinary Approach to Improve Pain Management and Satisfaction in a Trauma Population. In: Journal of Trauma Nursing. Lippincott Williams and Wilkins; 2020. p. 96–103.

27. Yemitan OK, Adeyemi OO. Mechanistic assessment of the analgesic, anti-inflammatory and antipyretic actions of Dalbergia saxatilis in animal models. Pharm Biol. 2017;55(1):898–905.

28. Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol (Paris). 2020 May 1;176(5):325–52.

29. White PF. What are the advantages of non-opioid analgesic techniques in the management of acute and chronic pain? Vol. 18, Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd; 2017. p. 329–33.

30. Chelly J, Wardhan R. Recent advances in acute pain management: Understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy. Vol. 6, F1000Research. Faculty of 1000 Ltd; 2017.

31. Dalal S, Bruera E. Pain Management for Patients With Advanced Cancer in the Opioid Epidemic Era. 2024; Available from: https://doi.org/

32. Woolf CJ. Capturing Novel Non-opioid Pain Targets. Vol. 87, Biological Psychiatry. Elsevier USA; 2020. p. 74–81.

33. Albrecht E, Chin KJ. Advances in regional anaesthesia and acute pain management: a narrative review. Vol. 75, Anaesthesia. Blackwell Publishing Ltd; 2020. p. e101–10.

34. Stein C. Opioid analgesia: recent developments. Vol. 14, Current Opinion in Supportive and Palliative Care. Lippincott Williams and Wilkins; 2020. p. 112–7.

35. Busserolles J, Lolignier S, Kerckhove N, Bertin C, Authier N, Eschalier A. Replacement of current opioid drugs focusing on MOR-related strategies. Vol. 210, Pharmacology and Therapeutics. Elsevier Inc.; 2020.

36. Urman RD, Chen R, Coppes OJM. Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies. Available from: www.painphysicianjournal.com

37. Da Costa BR, Pereira T V., Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: Network meta-analysis. The BMJ. 2021 Oct 12;375.

38. Rawat C, Kukal S, Dahiya UR, Kukreti R. Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. Vol. 16, Journal of neuroinflammation. NLM (Medline); 2019. p. 197.

39. Li JX, Zhang Y. Emerging drug targets for pain treatment. Eur J Pharmacol. 2012 Apr 15;681(1–3):1–5.

40. Thomas AM, Atkinson TJ. Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication Management? Journal of Pain. 2018 Jan 1;19(1):1–9.

41. Bernatoniene J, Sciupokas A, Kopustinskiene DM, Petrikonis K. Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain. Vol. 15, Pharmaceutics. Multidisciplinary Digital Publishing Institute (MDPI); 2023.

42. Denk F, Bennett DL, Mcmahon SB. Nerve Growth Factor and Pain Mechanisms. 2024;13:6. Available from: https://doi.org/10.1146/annurev-neuro-072116-

43. Carleton LA, Chakravarthy R, van der Sloot AM, Mnich K, Serrano L, Samali A, et al. Generation of rationally-designed nerve growth factor (NGF) variants with receptor specificity. Biochem Biophys Res Commun. 2018 Jan 1;495(1):700–5.

44. Rocco ML, Soligo M, Manni L, Aloe L. Nerve Growth Factor: Early Studies and Recent Clinical Trials. Curr Neuropharmacol. 2018 Apr 13;16(10):1455–65.

45. Mai L, Huang F, Zhu X, He H, Fan W. Role of nerve growth factor in orofacial pain. Vol. 13, Journal of Pain Research. Dove Medical Press Ltd.; 2020. p. 1875–82.

46. Baskaran P, Karthikeayan V, Natarajan A. Recent advances in pain management. Int J Basic Clin Pharmacol. 2020 Dec 23;10(1):133.

47. Ryan Patel C, Patel R, Montagut-Bordas C, Dickenson AH. Calcium channel modulation as a target in chronic pain control LINKED ARTICLES. Br J Pharmacol [Internet]. 2018;175:2173. Available from: http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc

48. Lenaeus MJ, Gamal El-Din TM, Ing C, Ramanadane K, Pomès R, Zheng N, et al. Structures of closed and open states of a voltage-gated sodium channel. Proc Natl Acad Sci U S A. 2017;114(15):E3051–60.

49. Catterall WA, Lenaeus MJ, Gamal El-Din TM. Structure and Pharmacology of Voltage-Gated Sodium and Calcium Channels. Annual Review of Pharmacology and Toxicology Downloaded from www.annualreviews.org Guest (guest [Internet]. 2019;12(4):54. Available from: https://doi.org/10.1146/annurev-pharmtox-010818-

50. Starowicz K, Finn DP. Cannabinoids and Pain: Sites and Mechanisms of Action. In: Advances in Pharmacology. Academic Press Inc.; 2017. p. 437–75.

51. Śmiarowska M, Białecka M, Machoy-Mokrzyńska A. Cannabis and cannabinoids: pharmacology and therapeutic potential. Vol. 56, Neurologia i Neurochirurgia Polska. Via Medica; 2022. p. 4–13.

52. Pergolizzi Jr J, Varrassi G. The Emerging Role of Sigma Receptors in Pain Medicine. Cureus. 2023 Jul 28;

53. Ruiz-Cantero MC, González-Cano R, Tejada M, Santos-Caballero M, Perazzoli G, Nieto FR, et al. Sigma-1 receptor: A drug target for the modulation of neuroimmune and neuroglial interactions during chronic pain. Vol. 163, Pharmacological Research. Academic Press; 2021.

54. Carpi M, Mercuri NB, Liguori C. Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer's Disease and Associated Sleep Disorders. Drugs. 2024;

55. Winrow CJ, Renger JJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia Keywords orexin receptor antagonist; insomnia; GABA; sleep. 2013; Available from: http://dx.doi.org/10.1111/bph.2014.171.issue-2

56. Muehlan C, Roch C, Vaillant C, Dingemanse J. The orexin story and orexin receptor antagonists for the treatment of insomnia. Vol. 32, Journal of Sleep Research. John Wiley and Sons Inc; 2023.

57. Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: Frommechanisms to treatment. Physiol Rev. 2021 Jan 1;101(1):259–301.

58. Bannister K, Sachau J, Baron R, Dickenson AH. Neuropathic Pain: Mechanism-Based Therapeutics. Annu Rev Pharmacol Toxicol [Internet]. 2024;(10):54. Available from: https://doi.org/10.1146/annurev-pharmtox-010818-

59. Ghazisaeidi S, Muley MM, Salter MW. Neuropathic Pain: Mechanisms, Sex Differences, and Potential Therapies for a Global Problem. The Annual Review of Pharmacology and Toxicology is Downloaded from www.annualreviews.org Guest (guest [Internet]. 2024;12:34. Available from: https://doi.org/10.1146/annurev-pharmtox-051421-

60. Viswanath Ivan Urits James Burns Karina Charipova Kyle Gress Alexandra McNally Richard Urman Ali Welschmeyer Amnon A Berger Hisham Kassem Manuel G Sanchez Alan D Kaye Treniece N Eubanks Elyse M Cornett Anh L Ngo OD. Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations. Adv Ther [Internet]. 37. Available from: https://doi.org/10.6084/

61. Giovannini S, Coraci D, Brau F, Galluzzo V, Loreti C, Caliandro P, et al. Neuropathic pain in the elderly. Vol. 11, Diagnostics. Multidisciplinary Digital Publishing Institute (MDPI); 2021.

62. Ahmedzai SH. Personalized medicine-one size fits one: Tailoring pain therapy to individuals' needs. J Pain Palliat Care Pharmacother. 2013 Mar;27(1):83–5.

63. Ting S, Schug S. The pharmacogenomics of pain management: Prospects for personalized medicine. Vol. 9, Journal of Pain Research. Dove Medical Press Ltd.; 2016. p. 49–56.

64. Cascella M, Petrucci E, Marinangeli F, Vittori A. "Emerging Topics in Pain Medicine": Advancing Research and Patient-Centered Health Strategies. Vol. 13, Journal of Personalized Medicine. Multidisciplinary Digital Publishing Institute (MDPI); 2023.

65. Kaye AD, Koress CM, Novitch MB, Jung JW, Urits I, Viswanath O, et al. Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review. Vol. 34, Best Practice and Research: Clinical Anaesthesiology. Bailliere Tindall Ltd; 2020. p. 651–62.

66. Hayashi M, Hamdy DA, Mahmoud SH. Applications for pharmacogenomics in pharmacy practice: A scoping review. Vol. 18, Research in Social and Administrative Pharmacy. Elsevier Inc.; 2022. p. 3094–118.

67. Wong AK, Somogyi AA, Rubio J, Philip J. The Role of Pharmacogenomics in Opioid Prescribing. Curr Treat Options Oncol. 2022 Oct 1;23(10):1353–69.

68. Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Vol. 14, Genomics, Proteomics and Bioinformatics. Beijing Genomics Institute; 2016. p. 298–313.

69. Javdan B, Lopez JG, Chankhamjon P, Lee YCJ, Hull R, Wu Q, et al. Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22.

70. Nijs J, George SZ, Clauw DJ, Fernández-de-las-Peñas C, Kosek E, Ickmans K, et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Vol. 3, The Lancet Rheumatology. Lancet Publishing Group; 2021. p. e383–92.

71. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93.

72. Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: towards precision medicine. Vol. 21, Nature Reviews Drug Discovery. Nature Research; 2022. p. 224–44.

73. Shi Y, Wu W. Multimodal non-invasive non-pharmacological therapies for chronic pain: mechanisms and progress. Vol. 21, BMC Medicine. BioMed Central Ltd; 2023.

74. Reebye R, Jacinto LJ, Balbert A, Biering-Soerensen B, Carda S, Draulans N, et al. Multimodal therapy and use of adjunctive therapies to BoNT-A in spasticity management: defining terminology to help enhance spasticity treatment. Front Neurol. 2024 Aug 30;15.

75. De Crescenzo F, Cortese S, Adamo N, Janiri L. Pharmacological and non-pharmacological treatment of adults with ADHD: A meta-review. Vol. 20, Evidence-Based Mental Health. BMJ Publishing Group; 2017. p. 4–11.

76. Viswanath Ivan Urits James Burns Karina Charipova Kyle Gress Alexandra McNally Richard Urman Ali Welschmeyer Amnon A Berger Hisham Kassem Manuel G Sanchez Alan D Kaye Treniece N Eubanks Elyse M Cornett Anh L Ngo OD. Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations. Adv Ther [Internet]. 37. Available from: https://doi.org/10.6084/

77. Manworren RCB. Multimodal pain management and the future of a personalized medicine approach to pain. AORN J. 2015 Mar 1;101(3):307–18.

78. Lagreca E, Onesto V, Di Natale C, La Manna S, Netti PA, Vecchione R. Recent advances in the formulation of PLGA microparticles for controlled drug delivery. Vol. 9, Progress in Biomaterials. Springer Science and Business Media Deutschland GmbH; 2020. p. 153–74.

79. Di Sarno L, Gatto A, Korn D, Pansini V, Curatola A, Ferretti S, et al. Pain management in pediatric age. An update. Vol. 94, Acta Biomedica. Mattioli 1885; 2023.

80. Al-Worafi YM. Safety of medications in special population. In: Drug Safety in Developing Countries: Achievements and Challenges. Elsevier; 2020. p. 143–62.

81. Semerci R, Akgün Kostak M, Eren T, Avci G. Effects of Virtual Reality on Pain During Venous Port Access in Pediatric Oncology Patients: A Randomized Controlled Study. Journal of Pediatric Oncology Nursing. 2021 Mar 1;38(2):142–51.

82. Koller G, Schwarzer A, Halfter K, Soyka M. Pain management in opioid maintenance treatment. Vol. 20, Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd; 2019. p. 1993–2005.

83. Craig KD, Holmes C, Hudspith M, Moor G, Moosa-Mitha M, Varcoe C, et al. Pain in persons who are marginalized by social conditions. Vol. 161, Pain. NLM (Medline); 2020. p. 261–5.

84. Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, et al. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat Rev Neurol. 2020 Jul 1;16(7):381–400.

85. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Vol. 161, Pain. Lippincott Williams and Wilkins; 2020. p. 1976–82.

86. Davis KD, Flor H, Greely HT, Iannetti GD, MacKey S, Ploner M, et al. Brain imaging tests for chronic pain: Medical, legal and ethical issues and recommendations. Nat Rev Neurol. 2017 Oct 1;13(10):624–38.

87. Akdeniz M, Yardımcı B, Kavukcu E. Ethical considerations at the end-of-life care. Vol. 9, SAGE Open Medicine. SAGE Publications Ltd; 2021.

88. Manhapra A, Sullivan MD, Ballantyne JC, MacLean RR, Becker WC. Complex Persistent Opioid Dependence with Long-term Opioids: a Gray Area That Needs Definition, Better Understanding, Treatment Guidance, and Policy Changes. Vol. 35, Journal of General Internal Medicine. Springer; 2020. p. 964–71.

89. Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF. Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. Vol. 23, Current Treatment Options in Oncology. Springer; 2022. p. 348–58.

90. Sturdivant T, Amiri A. Ethical Decision-Making for Nurses Treating Acute Pain in Patients with Opioid Abuse History [Internet]. Available from: https://www.researchgate.net/publication/339067544

91. Ferry B, Gervasoni D, Vogt C. Regulatory and Ethical Considerations. In: Stereotaxic Neurosurgery in Laboratory Rodent. Springer Paris; 2014. p. 1–18.

92. Liang Z, Lai Y, Li M, Shi J, Lei CI, Hu H, et al. Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications. Vol. 16, Chinese Medicine (United Kingdom). BioMed Central Ltd; 2021.

93. Eder C, Wild C. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption. Vol. 7, Journal of Market Access and Health Policy. Routledge; 2019.

94. Melis M, Meringer R, McCulloch K, et al. G-protein-coupled receptor modulators as novel pain therapeutics. *Front Pharmacol*. 2023;14:1021.

95. Smith JD, Robbins KE, Hill JR, et al. Selective targeting of Nav1.7 sodium channels for chronic pain treatment. *J Med Chem*. 2022;65(18):10234-10247.

96. Linder S, Brenner G, Zimmermann M, et al. Closed-loop spinal cord stimulation: Advances and future perspectives. *Neurosurg Rev*. 2024;47(4):659-667.

97. Turner S, Blair D, Jones A, et al. Genetic predictors of pain sensitivity and treatment response. *Pain Med*. 2023;24(8):1411-1422.

98. Li W, Guo Y, Zhao Y, et al. Functional neuroimaging in pain management: New frontiers. *J Clin Neurosci*. 2024;31:58-65.

99. Zhang H, Liu Y, Wang T, et al. Stem cell-based therapies for chronic pain: Current state and future directions. *Regener Med*. 2023;18(2):145-156.

100. Alorfi NM. Pharmacological Methods of Pain Management: Narrative Review of Medication Used. Int J Gen Med. 2023 Jul;Volume 16:3247–56.

101. Karanikolas M, Swarm RA. CURRENT TRENDS IN PERIOPERATIVE PAIN MANAGEMENT.